top of page

Coave Therapeutics and Théa Open Innovation sign exclusive agreement

Two agree to licensing, co-development, and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Press Release

Paris, France, 16th September 2021 – Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, has entered into an exclusive licensing, co-development and commercialization agreement with Théa, a leading European speciality Pharma focused on ophthalmology. The agreement covers Coave’s lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).

“We are delighted to sign this agreement with Théa for CTx-PDE6b, our most advanced candidate, which represents an innovative new gene therapy for people with Retinitis Pigmentosa,” said Rodolphe Clerval, CEO of Coave. “Théa is a leading European speciality pharma company in the field of Ophthalmology with world-class development expertise and commercial capabilities in major markets worldwide. We are very excited about the potential of CTx-PDE6b and look forward to building a successful relationship with Théa, as we advance this novel candidate through clinical development.”

To read entire press release click here


Contact Information

Coave Therapeutics Rodolphe Clerval, CEO

MEDiSTRAVA Consulting Sylvie Berrebi, Eleanor Perkin, Mark Swallow PhD Tel: +44 (0)7714 306525

Laboratoires Théa Lorraine Kaltenbach, Director of Communication

bottom of page